A Case of Conversion Hepatectomy for Hepatocellular Carcinoma with Vascular Invasion after Atezolizumab-bevacizumab Treatment

DOI 機関リポジトリ オープンアクセス
  • Takada Musashi
    Department of Surgery, Dokkyo Medical University, Saitama Medical Center
  • Tajima Hidehiro
    Department of Surgery, Dokkyo Medical University, Saitama Medical Center
  • Noro Takuji
    Department of Surgery, Dokkyo Medical University, Saitama Medical Center
  • Kawasaki Keishi
    Department of Surgery, Dokkyo Medical University, Saitama Medical Center
  • Tatsuoka Teppei
    Department of Surgery, Dokkyo Medical University, Saitama Medical Center
  • Okuyama Takashi
    Department of Surgery, Dokkyo Medical University, Saitama Medical Center
  • Kusano Yumi
    Department of Gastroenterology, Dokkyo Medical University, Saitama Medical Center
  • Ban Shinichi
    Department of Pathology, Dokkyo Medical University, Saitama Medical Center
  • Tamano Masaya
    Department of Gastroenterology, Dokkyo Medical University, Saitama Medical Center
  • Yoshitomi Hideyuki
    Department of Surgery, Dokkyo Medical University, Saitama Medical Center

この論文をさがす

抄録

<p>We report a hepatocellular carcinoma (HCC) case with vascular invasion successfully treated by conversion hepatectomy after treatment by atezolizumab-bevacizumab. A 74-year-old male patient was diagnosed with HCC and referred to our hospital. The tumor at the anterior section was 12.3 cm in diameter. It had invaded a portal vein branch of subsection 5 (S5) and peripheral branches of the middle hepatic vein. Serum alpha-fetoprotein (AFP) level was extremely high at 177408.3 ng/ml. The patient first received atezolizumab-bevacizumab treatment. After three cycles of atezolizumab-bevacizumab therapy, the tumor had decreased in size, the invasion into a portal and hepatic vein disappeared, the tumor enhancement completely vanished in the CT scan, and the tumor markers became within normal range. We decided to perform a conversion hepatectomy. The tumor was removed entirely by S5 partial resection, and pathological analyses showed a complete response to atezolizumab-bevacizumab treatment. There was no perioperative complication. The patient has survived for nine months without recurrence so far. Atezolizumab combined with bevacizumab might be an effective and appropriate option for the multidisciplinary treatment aiming for curative surgical resection.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ